SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$90.25
−2.62%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.23x
- Price / sales
- 87.94x
- Price / cash flow
- -38.09x
Enterprise value
- Enterprise value
- $7.0B
- EV / sales
- 76.90x
- EV / EBITDA
- -37.50x
- EV / EBIT
- -34.56x
- Market cap
- $8.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026